

**Armen Krikor Goenjian, M.D., D.F.A.P.A., F.A.C.G.S.**  
Collaborative Neuroscience Network, LLC  
19401 S. Vermont Avenue, Suite F-100  
Torrance, CA 90502

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

**AFFILIATIONS:**

Collaborative Neuroscience Network, LLC  
12772 Valley View Street, Suite 3  
Garden Grove, CA 92845

Collaborative Neuroscience Network, LLC  
2600 Redondo Avenue, Suites 415 & 500  
Long Beach, CA 90806

Ocean View Psychiatric Health Facility  
2600 Redondo Avenue, Suites 415 & 500  
Long Beach, CA 90806

Del Amo Hospital  
23700 Camino del Sol  
Torrance, CA 90505

Pacific Hospital of Long Beach  
2776 Pacific Avenue  
Long Beach, CA 90806

**EDUCATION:**

1970 Doctor of Medicine  
University of Tennessee, Memphis, Tennessee

1968 Bachelor of Science  
American University of Beirut, Beirut, Lebanon

**INTERNSHIP AND RESIDENCIES:**

1972-1975 Residency Training in Psychiatry  
University of California Los Angeles, Los Angeles, California and  
Veterans' Administration, Sepulveda, California

1971-1972 Memorial Medical Center of Long Beach, California

**CERTIFICATION:**

Certified by the American Board of Psychiatry and Neurology in Psychiatry

**LICENSURE:**

Licensed Physician and Surgeon, State of California, License No. C34978

**PROFESSIONAL EXPERIENCE:**

*Medical Director/Investigator*, 2000-Present  
Collaborative Neuroscience Network, LLC

*Research Professor of Psychiatry*, 2002-Present  
University of California, David Geffen School of Medicine, Los Angeles

*Private Practice*, 1975-Present  
Los Angeles, California

*Medical Director, Adult and Geriatric Psychiatry Program*, 1994-2013  
Pacific Hospital of Long Beach, California

*Medical Director, Adult and Geriatric Psychiatry Program*, 2002-2012  
Community Hospital of Long Beach, California

*National Center for Child Traumatic Stress Terrorism and Disaster Branch Consultant*,  
2001-Present

*Senior Medical Director*, 1994-Present  
Memorial Counseling Associates

*Medical Director, Outpatient Program*, 1998-1999  
Behavioral Health Services – PMR

*Associate Research Psychiatrist*, 1996-2002  
University of California, Los Angeles

**PROFESSIONAL EXPERIENCE (continued):**

*Psychiatric Consultant*, 1996-1998  
Army of the Republic of Armenia

*Medical Director, Partial Hospitalization Program*, 1995-1999  
University of California Irvine – PMR

*Visiting Associate Professor, Department of Psychiatry and Behavioral Sciences*, 1993-1995  
University of California, Los Angeles

*Medical Director of Psychiatry*, 1988-1994  
Alondra Crest Hospital, Bellflower, California

*Chairman, Department of Psychiatry*, 1983-1986  
Memorial Medical Center of Long Beach, California

*Vice Chairman, Department of Psychiatry*, 1981-1983  
Memorial Medical Center of Long Beach, California

*Acting Medical Director*, 1981-1982  
Alcohol Treatment and Education Center of Long Beach, California

*Consultant*, 1978-1985  
State Department of Mental Health, Long Beach, California

*Staff Psychiatrist, Adult Outpatient Clinic*, 1975-1976  
Harbor General Hospital, Carson, California

*Part-time Physician*, 1973-1974  
Northeast Health Center Methadone Clinic, Los Angeles, California

*Staff Physician, Internal Medicine*, 1971  
Santa Fe Memorial Hospital, Los Angeles, California

**COMMITTEES:**

*Chairman, Alcoholic Committee*, 1980-1983  
Memorial Medical Center, Long Beach, California

*Chairman, Psychiatric Utilization Committee*, 1978-1986  
Long Beach Memorial Hospital, Long Beach, California

**INVESTIGATOR EXPERIENCE:**

Phase I • Alzheimer's Disease • Anxiety • Bipolar Disorder • Depression • Dementia  
Fibromyalgia • Insomnia • Mild Cognitive Impairment • Post Traumatic Stress Disorder (PTSD)  
• Schizophrenia and Schizoaffective Disorders • Tardive Dyskinesia • Smoking Cessation

**CLINICAL TRIAL EXPERIENCE:**

***Phase I Alzheimer's***

A Phase I, FIM, Double-Blind, Randomized, Placebo-Controlled, Multiple Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of XXX in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXX in Subjects With Mild to Moderate Alzheimer's disease

***Phase I Depression***

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Multiple Oral Doses of XXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

A Phase I, multi-center, randomized, double-blind placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of ascending high doses of xxx as adjunctive therapy in the treatment of subjects with major depressive disorder

A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of XXX in Major Depressive Disorder Subjects

***Phase I Schizophrenia and Schizoaffective Disorders***

A Phase Ib, Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Schizophrenia Patients Already Stabilized on XXX

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Different Molecular Weights (Low, and High Molecular Weights as Test Treatments) of XXX Compared to Intermediate Molecular Weight (Reference Treatment) of XXX in Treatment-Seeking Subjects with Schizophrenia

A Phase I, Multi-center, Randomized, Double-Blind, Comparator-Controlled Study to Assess the Tolerability, Safety, Efficacy, and Pharmacokinetics of Ascending Multiple Oral Doses of XXX in Adult Subjects with a Diagnosis of Schizophrenia or Schizoaffective Disorder

A Phase I, Parallel-group, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of XXX on QT/QTc in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I, 2-part, open label, inpatient study to assess the safety and tolerability of multiple ascending doses of XXX in subjects with schizophrenia

A Phase I, Evaluation of The Effects of Sequential Multiple-Dose Regimens of XXX on Cardiac Replolarization in Patients with Schizophrenia

A Phase I Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of XXX a 3-Month Formulation in Subjects with Schizophrenia

A Phase I, Two-Period, Two Treatment, Two-Way Steady-State Crossover Bioequivalence Study of XXX Tablets under Fasting Conditions

A Phase I Two-Period, Two-Treatment, Open-Label, Two-Way Steady-State Crossover Bioequivalence Study of XXX Extended Release Tablets Under Fasting Conditions in Patients

A Phase I Study Investigating the Potential Interaction between XXX and Antipsychotic Treatments in Subjects with Schizophrenia or Schizoaffective Disorder

An Open-label, Parallel-arm, Two-period, Single-dose Pilot Study to Assess the Pharmacokinetics and the Effect of Food on the Pharmacokinetics of Five Once Weekly Oral Formulations of XXX on Adult Subjects with Schizophrenia

A Phase I, Comparative, Randomized, 2-way Crossover Bioavailability Study of XXX Tablets and XXX Tablets Under Fasting Conditions at Steady State in Subjects with Schizophrenia

A Multi-center Double-Blind, Randomized, Parallel Group, Active-Controlled Tolerability and Safety Study of XXX in Clinically Stable Schizophrenic Outpatients

**CLINICAL TRIAL EXPERIENCE (continued):**

A Placebo- and Positive-Controlled, Randomized Study, Evaluating Qt and Qtc Intervals Following Administration of Immediate-Release an Atypical Antipsychotic in Subjects with Schizophrenia or Schizoaffective Disorder.

A Phase I, Double Blind, Randomized, Placebo- Controlled Study Evaluating QT/ QTc Intervals Following Administration of XXX and XXX in Subjects With Schizophrenia or Schizoaffective Disorder

A Phase I, Open-label parallel arm multiple dose tolerability, pharmacokinetics and safety study in adult patients with Schizophrenia following administration of XXX IM depot formulation once every four weeks.

***Phase I Other***

A Phase I, Reliability and validity of an online neurocognitive test battery, the XXX Test, in normal healthy adults

A Randomized, Open-Label, Three-Period Cross-Over Study in Healthy Subjects to Compare the Pharmacokinetic Profiles of a 7-Day Application of the XXX to Three Different Skin Sites

***Phase II-IV***

***Alzheimer's Disease***

A Phase IIIb, XXX , Impact of PET on the Clinical Diagnosis and Management of Patients with Progressive Cognitive Decline

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type

A One-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Medication Approved for the Treatment of Parkinson's Disease Added to a Medication Approved for Memory Impairment and Dementia Daily in Patients with Mild to Moderate Dementia of the Alzheimer's Type

A Multi-center, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

A Phase II, Double Blind, Randomized, Placebo-Controlled, Multi-center, Dose-Ranging, Parallel-Group, Study to Evaluate the Safety and Efficacy of Oral XXX in Patients with Mild to Moderate Alzheimer's Disease

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase IIb Nicotinic Agonist Alzheimer's Disease trial, Dose Ranging, Randomized, Double-Blind, Parallel-Group, Placebo-Controller, Multi-center Study of XXX Used as Add-On to XXX Treatment in Patients with Mild to Moderate Symptoms of Alzheimer's Disease

A Phase III Multi-center, Randomized, Placebo-Controlled, Double-Blind, Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease on XXX

A Phase III, Multi-center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in subjects with Alzheimer's Disease who Participated in Study XXX or in Study XXX

A Phase III, Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Efficacy And Safety Trial Of XXX in Patients With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein E 4 Non-Carriers

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

***Anxiety***

A Prospective Randomized Clinical Study to Evaluate the Clinical Impact of Pharmacogenetic-Guided Treatment for Depression and Anxiety

A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release XXX for the Treatment of Generalized Anxiety Disorder (GAD)

A Novel Anxiolytic Versus Placebo in Generalized Anxiety Disorder: A Randomized Double-Blind Placebo and XXX Controlled Fixed Dose Parallel Group Multi-center Study of 10 Weeks

***Bipolar Disorder***

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder

A Multicenter, Randomized, Double-blind Trial of XXX versus Placebo for the Acute Treatment of Subjects Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter, Fixed Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of XXX in Patients with Bipolar I Depression

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder

A Phase IIIb, Double-Blind, Placebo-Controlled Trial of XXX in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects with Bipolar I Disorder

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day XXX 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day XXX Tablet for Sublingual Administration XXX 0.1 mg, 0.4 mg, and 0.8 mg In the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate

A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of XXX for Inhalation in Patients with Bipolar I Disorder and Agitation

A Phase III, Randomized, 6-Week, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of XXX for the Treatment of Bipolar I Depression in Subjects Demonstrating non-response to Treatment with XXX alone AND A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar I Depression

A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of XXX with XXX During Initial Dose Escalation in Patients with Bipolar Depression

A Six-Week, Double-Blind, Multi-center, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral XXX as Add-on, Adjunctive Therapy with XXX, XXX, or XXX in Bipolar I Depression

A Confirmatory Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Use of an Atypical Antipsychotic in the Treatment of Patients with Bipolar Depression

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Trial of the Use of a Novel Antipsychotic in the Treatment of Patients with Bipolar Depression



**CLINICAL TRIAL EXPERIENCE (continued):**

A Multi-center, Randomized, Double-Blind, Placebo Controlled Clinical Research Study to Evaluate the Safety and Efficacy of XXX in Patients with Acute Mania in Bipolar Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multi-center Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release XXX in the Treatment of Subjects with Acute Manic and Mixed Episodes Associated with Bipolar I Disorder

A Multi-center, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of an Atypical Antipsychotic to Placebo When Used as Adjunct to Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

An Anti-Seizure Medication Versus Placebo as Add-on Treatment in Subjects with Bipolar Disorder in the Outpatient Setting

A Phase III, Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment with a Novel Antipsychotic Subjects with Mania

A Placebo-Controlled 21-Day Study of the Safety and Efficacy of XXX for the Treatment of Treatment-Resistant Bipolar I Disorder with an Optional Open-Label Extension.

A Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release XXX in Patients with Bipolar Disorder.

A Three-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release XXX in XXX-Failure Patients with Bipolar Disorder

A Six-Month, Open-Label, Multi-center Study of Extended Release XXX in Patients with Bipolar Disorder – an Extension of Protocols XXX and XXX

A Multi-center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of XXX as Add-on therapy with XXX or XXX in the Treatment of Acute Mania

***Depression***

A Double-Blind, Placebo-Controlled, Fixed-Dose Study of XXX in Patients with Major Depressive Disorder

A Phase IIb, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of XXX in Adult Patients with Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase II, Open-label, 8-Week Study of Safety and Efficacy for Adjunctive XXX Treatment in Adults with Parkinson's Disease and Inadequately Controlled Depression

A Phase II, Depression Diagnostic Aid Confirmatory Performance Study - An Abbreviated Investigational Device Exemption Study

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive XXX in Major Depressive Disorder

A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study of XXX as Adjunctive Treatment to a monoaminergic antidepressant in Adults with Major Depressive Disorder

A Phase IIB Two-Stage, Multicenter, Double-blind, Randomized, Parallel Group, Active- and Placebo-Controlled, Adaptive Dose Finding Study to Assess the Efficacy and Safety of XXX as Adjunctive Therapy to an Antidepressant in Adult Subjects with Major Depressive Disorder who have Responded Inadequately to Antidepressant Therapy

A Phase III, 8-Week Prospective Randomized, Controlled, Single-Blind Trial of the XXX vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults with Major Depressive Disorder

A Phase III, Non-Interventional Study of Subjects who have participated in XXX, A Study of Adjunctive Treatment of Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Phase IV, Relapse Prevention Study Evaluating the Efficacy and Safety of XXX (5, 10 and 20 mg) in Adults with Major Depressive Disorder

A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy

A Phase III, Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

A Phase III, Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of XXX (1 and 3 mg/ day) as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate XXX in Subjects with Major Depressive Disorder and Inadequate Response to Antidepressant

A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of XXX Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment

A Phase III, Randomized, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of XXX on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD)

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension

A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD)

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of XXX as Monotherapy Treatment in Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Therapy

A Phase III Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral XXX Combination Therapy in Patients with Major Depressive Disorder

A 52-Week, Multi-center, Open-Label Study of the Safety and Tolerability of XXX Tablets in Patients with Major Depressive Disorder (MDD)

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

A Multi-center, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of an XXX Combination Therapy in Patients with Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Double-Blind, Placebo-Controlled Project of XXX to XXX Antidepressant Therapy (ADT) among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior ADT

A Study of Augmentation with XXX for Patients with Major Depressive Disorder who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

A Double-Blind, Placebo-Controlled Project of XXX Adjunctive to Antidepressant Therapy (ADT) Among Outpatients with Major Depressive Disorder Who Have Responded Inadequately to Prior ADT

A Six-Week, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Evaluating the Efficacy, Safety, and Tolerability of XXX Compared to Placebo in Female Subjects, Diagnosed with Major Depressive Disorder

A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Major Depressive Disorder

A Randomized Double Blind, Parallel Group, Placebo Controlled, Active Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of XXX in Acute Treatment of Adults with Major Depressive Disorder

A 12-Week Randomized Open-Label Trial of XXX vs. Generic SSRIs in the Treatment of a Severe Depressive Episode

A One Year Open label Study Assessing the Safety of XXX in Patients with Major Depressive Disorder

A Multi-center, Randomized, 24-52-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients with Major Depressive Disorder Who Achieved an Initial Response to 12 Weeks of Open-Label Treatment with XXX Once Daily

A Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of an Atypical Antipsychotic as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

The Depression Response to a Sleep Medication in Adults with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety and Efficacy Study of a Sleep Medication Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy, Safety, and Tolerability of a Once Daily Novel Antidepressant versus Placebo in Subjects with Major Depressive Disorder

A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Atypical Antipsychotic Augmentation of XXX Monotherapy in Young and Older Adult Patients with Unipolar Treatment-Resistant Depression.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of a New Anti-Depressant to Another Anti-Depressant to Placebo in Patients with Major Depressive Disorder.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study Evaluating Efficacy and Safety of XXX Controlled Release versus Placebo in Patients with Major Depressive Disorder

***Diabetes***

A Phase IIIb, 24-week, Randomised, Placebo-Controlled, Double-Blinded, Efficacy and Safety Study of XXX in Black/African American Patients with Type 2 Diabetes with a MTT Sub-Study

A Phase III 24-week, Multi-Centre, Randomized, Double-Blind, Age-Stratified, Placebo-Controlled Phase III Study with a 28-Week Extension Period to Evaluate the Efficacy and Safety of XXX 10 mg Once Daily in Patients with Type 2 Diabetes and Cardiovascular Disease, who Exhibit Inadequate Glycemic Control on Usual Care

***Epilepsy***

A Randomized, Double-Blind, Parallel-Group, Multi-center Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

An International, Double-Blind, Randomized, Multi-center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of XXX in Subjects ( $\geq 16$  to 75 years old) with Partial Onset Seizures with or without Secondary Generalization

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs And Long-Term Extension XXX Study for the XXX Double-Blind Monotherapy study

A Conversion to Monotherapy for Adults with Epilepsy Experiencing Partial Seizures (with or without Secondary Generalization), A Historical-controlled, Multi-center, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

**CLINICAL TRIAL EXPERIENCE (*continued*):**

***Fibromyalgia***

A Phase IIa, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of XXX in Subjects with Fibromyalgia

An Open-label Extension Study of XXX for 52 weeks in Pain Associated with Fibromyalgia

A randomized, double-blind, double-dummy, placebo- and active-controlled, multi-center study of XXX in subjects with pain associated with fibromyalgia

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of XXX to Evaluate Responsiveness of, and Estimate the Clinically Important Difference in, a Novel Fatigue Tool in Subjects with Fibromyalgia

A Phase III, Randomized Evaluation of a Low Frequency Investigational Device Employing Neuromodulation Therapy in Patients with Fibromyalgia: A Double-Blind, Placebo-Controlled Trial

***Insomnia***

A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel-Group Study of the Safety and Efficacy of XXX in Subjects With Insomnia Disorder

The Efficacy and Safety of a Hypnotic Sleep Maintenance Insomnia: A 12-Week Multi-center, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open-Treatment Phase Extension for 40 Weeks

An Evaluation of the Long-Term Efficacy and Safety of a Hypnotic Compared to Placebo, When Both are Administered Over a Long-Term Period “as Needed,” in Patients with Chronic Primary Insomnia

An Evaluation of the Long-Term Efficacy and Safety of a Sleep Medication Compared to Placebo, When Both are Administered Over a Long-Term Period “as Needed,” in Patients with Chronic Primary Insomnia (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase IIIb Clinical Study)

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Eight-Week, Safety and Efficacy Study of a Novel Sleep Agent Compared to Placebo in Subjects with Major Depressive Disease and Insomnia

A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of XXX in Patients with Primary Insomnia Characterized by Difficulty in Maintaining Sleep

**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase II Randomized, Double-Blind, Placebo-and Active-Comparator-Controlled Study of the Safety and Efficacy of XXX in Outpatients with Insomnia

The Efficacy and Safety of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable Type II Diabetes Mellitus: A 12-Week Multi-center, Randomized, Double-Blind, Placebo-Controlled Study

***Post Traumatic Stress Disorder***

A 40-Week Open-Label Extension Study to Evaluate XXX SL Taken Daily at Bedtime in Patients with PTSD

A Phase III, 12-Week Open-Label Extension Study to Evaluate XXX Taken Daily at Bedtime in Patients with PTSD

A Phase II, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of XXX (1 - 3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder (PTSD)

A Phase III, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Taken Daily at Bedtime in Patients with Military-Related Post-traumatic Stress Disorder (PTSD)

A Phase II, 12-week, Open Label, Multicenter, Extension Study to Evaluate the safety and efficacy of XXX taken daily at bedtime in patients with military-related Post-traumatic Stress Disorder (PTSD) and related conditions

A Phase II, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Tablets Taken at Bedtime in Subjects with Military Related Post-Traumatic Stress Disorder (PTSD)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dose Study Evaluating the Efficacy and Safety of the XXX in Posttraumatic Stress Disorder (PTSD)

***Schizophrenia and Schizoaffective Disorders***

A Phase III, Multicenter, Multi-national, Double-blind (DB), Placebo-controlled, Randomized-Withdrawal Study Evaluating the Safety and Efficacy of XXX Compared with Placebo in the Prevention of Relapse in Patients with Schizophrenia

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics

A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Mono-Therapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of XXX in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 36-Week Open-Label Extension

A Phase III, Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients with Schizophrenia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of XXX using XXX as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia

A Phase IIb/III, Adaptive, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

A Phase III, 52-Week, Open-Label, Extension Study of XXX for the Adjunctive Treatment of Schizophrenia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive XXX for the Treatment of Schizophrenia

A Phase III Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

An Interventional, open-label, flexible-dose, long-term safety study of XXX in adult patients with schizophrenia

A Phase III, Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of XXX in Patients with Treatment-resistant Schizophrenia



**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase III, One Year, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as a Maintenance Treatment in Patients with Schizophrenia

A Phase III, Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

A Phase II, Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

An Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects with Schizophrenia

A Phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of 10 mg, 25 mg, 50 mg, and 100 mg once daily oral administration of XXX during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment

A Phase II, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerability of XXX in Subjects with Schizophrenia with Alcohol Use

An Exploratory, Multicenter, Open-label, Flexible-dose XXX Trial in the Treatment of Adults with Early-Episode Schizophrenia

A Phase III, Interventional, open-label, flexible-dose extension study of XXX once-monthly in patients with schizophrenia

A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia

A Phase II, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Schizophrenia to Mitigate or Prevent XXX -Induced Weight Gain

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose XXX in Acutely Psychotic Subjects with Schizophrenia

A Phase III, 28-week, Randomised, open-label study evaluating the effectiveness of XXX once-monthly versus XXX in adult patients with schizophrenia

A Phase III Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase III Study of 2 Doses of XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia

A Phase II, partial-blind, multi-center extension study to evaluate the long-term safety and health outcomes of XXX in subjects who completed Study XXX

A Phase IIb, 12 week randomized, double-blind, placebo-controlled, parallel group, multiple dose, proof-of-concept study to evaluate the effects of XXX on cognition in stable schizophrenia patients

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Non-smokers

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on XXX on Schizophrenia Negative Symptoms

A Phase III, 12-Week, Multicenter, Open-Label Extension Study In Subjects with Schizophrenia

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Phase II, Multicenter, Double-blind, Randomized, Fixed-dose, Parallel-group, 3-Week, Inpatient Treatment Study to Evaluate the Dose Response Relationship, Safety, Efficacy and Pharmacokinetics of XXX Compared with Placebo, using XXX as a Positive Control, in the Treatment of Acute Exacerbation of Schizophrenia

A Multicenter, open-label, single-arm flexible dose (20-80 mg twice daily, Phase III study of XXX in outpatients who complete (rollover) a previous XXX study and a study duration of up to 2 years after US XXX monotherapy launch.

A Phase III, Short-term, Multi-center, Placebo-controlled, Randomized Withdrawal Study of XXX with DSM-IV-TR Schizophrenia

A Double-blind, Placebo-controlled, Randomized Withdrawal Study of XXX for the Maintenance Treatment of Subjects with Schizophrenia

A Double-blind, Placebo and Active-controlled Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

**CLINICAL TRIAL EXPERIENCE (*continued*):**

Evaluation of the Long-term Safety, Tolerability and Pharmacokinetics of XXX in patients with Schizophrenia

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Phase III, Open-Label, Multicenter, Rollover, Long-term Study of XXX Intramuscular Depot in Patients with Schizophrenia

A Phase III, multi-center randomized, 24 week, double-blind, parallel group, placebo controlled study to evaluate efficacy and safety of XXX in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.

A Phase III, multi-center, randomized, 12 week, double-blind, parallel group, placebo-controlled study to evaluate efficacy and safety of XXX in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients with Schizophrenia receiving either Flexible Dose XXX or Placebo in long-term use (up to 26 weeks) followed by up to 52 weeks of Open-label Extension

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder

A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX

A Phase IIa, Multi-center, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Treatment Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Two Fixed Doses of XXX Compared to Placebo, Using XXX as an Active Control, in the Treatment of Acute Exacerbation of Schizophrenia

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible-Dose, Open-Label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of XXX in Stable Patients with Schizophrenia

A Double-Blind, Placebo-Controlled, Multi-center, Parallel Group Study to Assess Efficacy, Safety and Tolerability of XXX as Augmentation Therapy to Improve Cognition in Outpatients with Cognitive Dysfunction in Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

A Randomized Phase II, Double-Blind, Placebo-Controlled, Multi-center Study of XXX as Add-on Therapy in Outpatients with Persistent Negative Symptoms of Schizophrenia Treated with a Stable Dose of a Second Generation Antipsychotic

A 52-week, Multi-Center, Open-label Study to Evaluate the Effectiveness of as Maintenance Treatment in Patients with Schizophrenia

A One-Year Multinational, Multi-center, Randomized, Double-Blind, Parallel-Group, Fixed-Dose, XXX Study Combining a 12-Week Placebo-Controlled, XXX-Referenced Phase with a 12-Month XXX-Controlled Phase in Patients with Schizophrenia

A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of XXX versus XXX in Patients with Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB™)

A 24-Week, Multi-center, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of XXX and Placebo on Top of an Established Treatment Regimen of Either XXX, XXX/XXX, XXX or XXX Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia

A Phase II Six-Week, Double-Blind, Placebo-Controlled, Multi-center Trial of XXX for Cognitive Impairment in Subjects with Schizophrenia

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXX in Acutely Psychotic Patients with Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, XXX -Referenced, Parallel-Group Study of XXX in Subjects with Acute Exacerbations of Schizophrenia

The Long-Term Safety, Tolerability, and Effectiveness of XXX in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dosages of XXX in the Treatment of Subjects with Schizoaffective Disorder

A Multi-center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Double-Blind, Placebo Controlled Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the Safety and Efficacy of XXX Used as Augmentation Therapy in the Treatment of Patients with Chronic Schizophrenia Demonstrating an Inadequate Response to XXX or XXX Monotherapy

A Randomized Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXX Compared to XXX in Subjects with an Acute Exacerbation Schizophrenia

A Randomized, Double Blind, Multi-center Study to Assess the Antipsychotic and Motor Effects of XXX When Administered in Combination with XXX Or XXX to Schizophrenic Subjects

A Six-Week Multi-center, Randomized, Double-Blind, Placebo-Controlled, XXX-Referenced, Parallel Group Study to Assess the Safety and Efficacy of XXX in Subjects with Acute Exacerbations of Schizophrenia Requiring Hospitalization

A 12-week International, Multi-center, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release XXX in Patients with Schizophrenia

A Randomized Double-Blind, Placebo and XXX-Controlled, Multi-center Study to Evaluate the Efficacy and Safety and Tolerability of XXX Given BID to Schizophrenic Patients in Acute Exacerbation Followed by a Long-Term Treatment Phase

A Phase III, Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of XXX and Flexible Doses of XXX Long-Acting Intramuscular Injection in Subjects With Schizophrenia

A Multi-center, Randomized, Double-Blind, Fixed-Dose, Six-Week Trial of the Efficacy and Safety of an Atypical Antipsychotic in Development Compared with Placebo Using Another Atypical Antipsychotic Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Multi-center, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of an Atypical Antipsychotic in Development Using Another Atypical Antipsychotic Positive Control in Subjects

A Multi-center, Double-Blind, Flexible-Dose, Six-Month Trial Comparing the Efficacy and Safety of an Atypical Antipsychotic in Development with an Atypical Antipsychotic in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia

A Multi-center, Open-Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of an Atypical Antipsychotic and Another Atypical Antipsychotic in the Long-Term Treatment of Patients with Schizophrenia or Schizoaffective Disorder

A Multi-center, Randomized, Double-Blind Study on the Effects of an Atypical Antipsychotic on Overweight Patients Treated with Another Atypical Antipsychotic for Schizophrenia or Schizoaffective Disorder

A Four-Week Double Blind Multi-center Study Comparing the Efficacy and Safety of an Atypical Antipsychotic to Another Atypical Antipsychotic in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care

A Randomized, Double-Blind, Placebo-Controlled and an Atypical Antipsychotic-Referenced, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of an Atypical Antipsychotic in Development in the Treatment of Schizophrenia

A Double-Blind, Eight-Week, Placebo and XXX Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety, and Tolerability of a Novel Antipsychotic in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder

A Four-Week Double Blind Multi-center Study Comparing the Efficacy and Safety of a Novel Antipsychotic Compared to a Novel Antipsychotic in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care

An Assessment of the Efficacy and Safety of Two Sublingual Doses of a Novel Antipsychotic in Subjects with Schizophrenia (in an Acutely, Exacerbated State) Compared to Placebo in a Multi-center Randomized, Double-Blind, Fixed-Dose, Six-Week Trial with a XXX Positive Control Group

A Six-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of a Novel Antipsychotic Compared to Placebo and XXX in Patients with Schizophrenia Who are Experiencing an Acute Exacerbation of Symptoms

A 12-Week Multi-center Randomized, Double-Blind, Placebo-Controlled Evaluation of a Cognitive Enhancer as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patients with Schizophrenia and Schizoaffective Disorder

**CLINICAL TRIAL EXPERIENCE (continued):**

A Randomized, Double-Blind Study of the Safety and Efficacy of a Mood Stabilizer Plus an Atypical Antipsychotic Versus an Antipsychotic Alone in the Treatment of Schizophrenia

A Multi-center, Double-Blind, Placebo Controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of a Mood Stabilizer Versus Placebo as Add-on Therapy in Schizophrenia

A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of a Novel Antipsychotic Versus Placebo Versus XXX in Patients with Schizophrenia

A Trial of One Atypical Antipsychotic Versus Another Atypical Antipsychotic in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose XXX ER in the Treatment of Patients With Schizoaffective Disorder

A Phase IV Study to Measure Drug Satisfaction of Patients with Schizophrenia After Switching From XXX to XXX

***Tardive Dyskinesia***

A Phase III, Open-Label Rollover Study for Continuing XXX Administration for the Treatment of Tardive Dyskinesia

A Phase III, Open-Label, Safety and Tolerability Study of XXX for the Treatment of Tardive Dyskinesia

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel, Fixed-dose Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Tardive Dyskinesia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered XXX in Subjects with Drug-Induced Tardive Dyskinesia

***Other Indications***

A Phase IV, Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Study Evaluating the Effect of XXX 10 and 20 mg/day vs XXX 20 mg/day on Sexual Functioning in Healthy Subjects

**CLINICAL TRIAL EXPERIENCE (continued):**

A multi-center, multi-region, observational Smoking Cessation study to understand the biological or functional changes related to Smoking Cessation in apparently healthy smokers who are continuously abstinent from smoking for one year

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX In Subjects with Parkinson's Disease

A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Mild Cognitive Impairment

A One-Year, Multi-center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of a Medication Prescribed for Memory Impairment and Dementia in Subjects with Mild Cognitive Impairment

**OTHER CLINICAL AND POPULATION-BASED RESEARCH:**

Longitudinal Comorbidity Studies Among Children, Adolescents, and Adults Traumatized Due to the Spitak Earthquake of 1988. The studies were conducted over a span of eight years.

Neurohormonal Alterations Among Traumatized Adolescents, Including Studies of GPA Axis and Catecholimine System. 1993-1995

Controlled Treatment Outcome of School-Based Trauma/Grief Focused Psychotherapy Among Traumatized Adolescents. 1990-1991

Moral Development and Pathological Interference with Conscience Functioning Among Traumatized Adolescents. 1995

Comorbidity Studies Among Adolescents Traumatized Due to the War Between Azerbaijan and Karabagh. 1999

Comorbidity Studies Among Adolescents Traumatized Due to Hurricane Mitch. 1999

Relocation Studies of Children and Their Mothers Exposed to Earthquake. 1991

Epidemiological Survey of School-Aged Children in Ano Liosia Exposed to the Athens Earthquake. 2000

Collaborative Research (with UCLA Trauma Psychiatry Program, Olive View/UCLA Medical Center, Cornell Medical Center)

Behavioral Animal Model of PTSD



**OTHER CLINICAL AND POPULATION-BASED RESEARCH (continued):**

The Role of Traumatic Reminders and Adversities in the Course of PTSD Relocation among Traumatized Children, Adolescents, and Adults

**PUBLICATIONS:**

**Risk Factors Associated with Psychiatric Readmission.**

Lorine K., Goenjian H., Kim S., Steinberg A., Schmidt K., Goenjian A.  
JNMD (2015); 203: 425-430

**Loss and Psychosocial Factors as Determinants of Quality of Life in a Cohort of Earthquake Survivors.**

Khatchadourian V., Armenian H., Demirchyan A., Goenjian A.  
Health and Quality of Life Outcomes, Open Access (2015)

**Association of COMT and TPH-2 Genes with DSM-5 based PTSD Symptoms.**

Goenjian A.K., Noble E., Steinberg et al.  
Journal of Affective Disorders; on line published (October 22, 2014).

**Factor Structure and Psychometric Properties of the PTSD Checklist and DSM-5 PTSD Symptom Set in a Long-term Post-earthquake Cohort in Armenia.**

Demirchyan A., Goenjian A.K., Khatchadourian V.  
Assessment; Online published (October 27, 2014); pp 1-13.

**Association of TPH1, TPH2, and 5HTTLPR with PTSD and depression.**

Goenjian A.K., Bailey J.N., Walling D., et al.  
J Affect Disorder (2012); 140:244-252.

**Longitudinal study of PTSD, depression and quality of life among adolescents after the Parnitha earthquake.**

Goenjian A.K., Roussos A., Steinberg A.M., et al.  
J Affect Disorder (2011); 133(3)509-515

**A double-blind, randomized, placebo-controlled study of the dopamine D3 receptor antagonist ABT-925 in patients with acute schizophrenia.**

Redden L., Rendenbach-Muller B., Abi Saab W.M., Katz D.A., Goenjian A., et al.  
J Clinical Psychopharmacology (2011); 31(2) 221-225

**PTSD and Dopaminergic genes, DRD2 and DAT in multigenerational families exposed to the Spitak earthquake.**

Bailey J.N., Goenjian A.K., et al.  
Psychiatry Research (2010); 178 (3): 507-510.

**PUBLICATIONS (continued):**

**Depression and PTSD symptoms among bereaved adolescents 6(1/2) years after the 1988 Spitak earthquake in Armenia.**

Goenjian A.K., Walling D., Steinberg A.M., Roussos A., Goenjian H.A., Pynoos R.S.  
J Affect Disorder (2009 Jan); 112(1-3):81-4. Epub 2008 Jun 10.

**Heritabilities of symptoms of posttraumatic stress disorder, anxiety and depression in earthquake exposed Armenian families.**

Goenjian A.K., Noble E., et al.  
Psychiatric Genetics (2008); 18 (6):261-266

**A prospective study of posttraumatic stress and depressive reactions among treated and untreated adolescents 5 years after a catastrophic disaster.**

Goenjian A.K., Walling D., Steinberg A.M., Karayan I., Najarian L.M., Pynoos R.  
Am J Psychiatry (2005 Dec); 162(12):2302-230.

**Post-traumatic stress and depressive reactions among children and adolescents after the 1999 earthquake in Ano Liosia, Greece.**

Roussos A., Goenjian A.K., Steinberg A.M., Sotiropoulou C., Kakaki M., Kabakos C., Karagianni S., Manouras V.  
Am J Psychiatry (2005 Mar); 162(3):530-537

**Reverberations of danger, trauma and PTSD on group dynamics. In B. Skolerow, S.W. Twenlow, S. Wilkinson (Eds.), Analysts in the Trenches: Streets, Schools, War Zones.**

Pynoos R.S., Steinberg A.M., Dyb G., Goenjian A.K., Chen S.H., Brymer M.J.  
Hillsdale, NJ: The Analytic Press (2004)

**Fibromyalgia and psychopathology in a community hospital emergency room.**

Davidson P.W. and Goenjian A.K.  
Primary Psychiatry (2003); 10: 69-73

**Hypothalamic-pituitary-adrenal activity among Armenian adolescents with PTSD symptoms.**

Goenjian A.K., Pynoos R.S., Steinberg A.M., Endres D., Abraham K., Geffner M.E., Fairbanks L.A.  
J Trauma Stress (2003 Aug); 16(4):319-323.

**The effect of relocation after a natural disaster.**

Najarian L.M., Goenjian A.K., Pelcovitz D., Mandel F., Najarian B.  
J Trauma Stress (2001 Jul); 14(3):511-26.

**Post-traumatic stress and depressive reactions among Nicaraguan adolescents after hurricane Mitch.**

Goenjian A.K., Molina L., Steinberg A.M., Fairbanks L.A., Alvarez M.L., Goenjian H.A., Pynoos R.S.  
Am J Psychiatry (2001 May); 158(5):788-794.

**PUBLICATIONS (continued):**

***The Effect of Relocation After a Disaster.***

Najarian L.M., Goenjian A.K., Pelcovitz D., Mandel F., Najarian B.  
Journal of Traumatic Stress (2001); 14:511-526

***A Prospective study of posttraumatic stress, anxiety, and depressive reactions after earthquake and political violence.***

Goenjian A.K., Steinberg A.M., Najarian L.M., Fairbanks L.A., Tashjian M., Pynoos R.S.  
Am J Psychiatry (2000 Jun); 157(6):911-916.

***Are researchers bound by child abuse reporting laws?***

Steinberg A.M., Pynoos R.S., Goenjian A.K., Sossanabadi H., Sherr L.  
Child Abuse and Neglect (1999 Aug); 23(8):771-777.

***Moral development and psychopathological interference in conscience functioning among adolescents after trauma.***

Goenjian A.K., Stilwell B.M., Steinberg A.M., Fairbanks L.A., Galvin M.R., Karayan I., Pynoos R.S.  
Journal of American Academy Child Adolescent Psychiatry (1999 Apr); 38(4):376-84.

***Children & Disorders: A Developmental Approach to Posttraumatic Stress Disorder in Children and Adolescents.***

Pynoos R.S., Goenjian A.K., Steinberg A.M.  
Psychiatric & Clinical Neurosciences (1998); 52 (Suppl.) S129-138

***Outcome of Psychotherapy Among Early Adolescents After Trauma.***

Goenjian A.K., Karayan I., et al.  
Psychiatric Digest (1998); 1:22-23

***A public mental health approach to the postdisaster treatment of children and adolescents.***

Pynoos R.S., Goenjian A.K., Steinberg A.M.  
Child and Adolescent Psychiatric Clinics of North America (1998 Jan); 7(1):195-210, x.  
Review.

***Issues in the developmental neurobiology of traumatic stress.***

Pynoos R.S., Steinberg A.M., Ornitz E.M., Goenjian A.K.  
Annals of the New York Academy of Sciences (1997 Jun); 821:176-93. Review. No abstract available.

***Outcome of psychotherapy among early adolescents after trauma.***

Goenjian A.K., Karayan I., Pynoos R.S., Minassian D., Najarian L.M., Steinberg A.M., Fairbanks L.A.  
Am J Psychiatry (1997 Apr);154(4):536-542

**PUBLICATIONS (continued):**

**Basal cortisol, dexamethasone suppression of cortisol, and MHPG among adolescents after the 1988 earthquake in Armenia.**

Goenjian A.K., Yehuda R., Pynoos R.S., Steinberg A.M., Tashjian M., Yang R.K., Najarian L.M., Fairbanks L.A.  
Am J Psychiatry (1996 Jul);153(7):929-934.

**Posttraumatic stress reactions in children and adults: After the 1988 Spitak Earthquake in Armenia.**

Goenjian A.K.  
Prehospital and Disaster Medicine (1996); Volume 11 (2): 111.

**The 1988 Spitak Earthquake in Armenia: Implementation of a mental health program and clinical observations.**

Goenjian A.K.  
Prehospital and Disaster Medicine (1996); Volume 11 (2): 101-102.

**Relocation after a disaster: Posttraumatic stress disorder in Armenia after the earthquake.**

Najarian L.M., Goenjian A., Pelcovitz D., Najarian B.  
Journal of the American Academy of Child and Adolescent Psychiatry (1996); Volume 35: 374-383.

**Traumatic stress in children and adolescents: Recent trends and current controversies.**

Pynoos R.S., Steinberg A.M., Goenjian A.K.  
Traumatic Stress. Van der Kolk B., McFarlane A.C., Weiseth L., (eds.). New York Guilford Publications Inc. (1996); 331-358.

**A behavioral animal model of posttraumatic stress disorder featuring repeated exposure to situational reminders.**

Pynoos R.S., Ritzmann R.F., Steinberg A.M., Goenjian A.K., Prisecaru I.  
Biological Psychiatry (1996 Jan); 39(2):129-34.

**Psychiatric comorbidity in children after the 1988 earthquake in Armenia.**

Goenjian A.K., Pynoos R.S., Steinberg A.M., Najarian L.M., Asarnow J.R., Karayan I., Ghurabi M., Fairbanks L.A.  
Journal of the American Academy of Child and Adolescent Psychiatry (1995 Sept); Volume 34 (9): 1174- 1184.

**Strategies of disaster intervention for children and adolescents.**

Pynoos R.S., Goenjian A.K., Steinberg A.M., Najarian L.M., Asarnow J.R., Karayan I., Ghurabi M., Fairbanks L.A.  
Extreme Stress and Communities: Impact and Intervention. Hobfoll, SE and DeVries, M (eds.)  
Dordrecht, The Netherlands: M. Klumer, Academic Publishers, (1995) 445-471.

**PUBLICATIONS (continued):**

**Posttraumatic stress reactions after single and double trauma.**

Goenjian AK, Najarian LM, Pynoos RS, Steinberg AM, Petrosian P, Setrakyan S, Fairbanks LA. Acta Psychiatrica Scandinavica (1994 Sept); Volume 90(3):214-21.

**Post-traumatic stress disorder in elderly and younger adults after the 1988 earthquake in Armenia.**

Goenjian A.K., Najarian L.M., Pynoos R.S., Steinberg A.M., Manoukian G., Tavosian A., Fairbanks L.A.  
Am J Psychiatry (1994 Jun); Volume 151(6):895-901.

**Post-traumatic stress reactions in children after the 1988 Armenian earthquake.**

Pynoos R.S., Goenjian A.K., Tashjian M., Karakashian M., Manjikian R., Manoukian G., Steinberg A.M., Fairbanks L.A.  
British Journal of Psychiatry (1993 Aug); Volume 163:239-247.

**A mental health relief program in Armenia after the 1988 earthquake: Implementation and clinical observations.**

Goenjian A.K.  
British Journal of Psychiatry (1993 Aug); Volume 163:230-239.

**The economic consequences of psychological problems in Armenia. The economic restructuring of Armenia.**

Goenjian A.K.  
Proceedings of a Symposium by Armenian Engineers and Scientists of America, Los Angeles, California (1991 Feb 21-23).

**Cardiac arrhythmias in a population admitted to an acute alcoholic detoxification center.**

Buckingham T.A., Kennedy H.L., Goenjian A.K., Vasilomanolakis E.C., Shriver K.K., Sprague M.K., Lyyski D.  
American Heart Journal (1985 Nov); Volume 110:5,961-965.

**Effects of methadone on alcohol consumption and growth in mice.**

Goenjian A.K., Cummins J.T.  
Drug Alcohol Dependency (1975 Jun); 1:313-318.

**Alcoholism and methadone maintenance.**

Friedman R., Goenjian A.K., and Cummins J.T.  
Western Pharmacology (1974); 17: 132-134.

**HUMANITARIAN WORK:**

**Psychiatric Outreach Mental Health Relief Program in Armenia, 1989-1990**

Initiated and directed the Psychiatric Outreach Program in Soviet Armenia after the 1988 Spitak earthquake. The program sent over 60 mental health workers from the U.S. and Europe to provide direct patient care to the victims of the earthquake. Over 10,000 victims were evaluated and provided with brief and long-term psychotherapy. Provided direct therapeutic services to victims during bi-annual visits to Armenia.

**Armenian Relief Society Treatment and Training Program in Armenia, 1991-present**

Director of the psychiatric treatment and training program: initiated and supervised training program for local mental health professionals and paraprofessionals based on state-of-the-art Western therapeutic techniques; provided clinical consultation to local health professionals and psychiatric hospitals. Arranged for the building of two mental health clinics in the earthquake zone that employ the trained professionals. Yearly, 800-1,000 new patients are seen in these clinics. In addition, the program provides liaison service to local hospitals and consultation to schools. It also provides training to professionals and paraprofessionals from the war-ravaged Karabagh and direct clinical services to victims of the violence.